AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01329874 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Type of block injection
Description: Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
Study NCT00802035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen IR
Description: 30 mg; single dose
Study NCT00802035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen ER
Description: 30 mg; single dose
Study NCT04819516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-intensity focused ultrasound therapy
Description: Patients will receive high-intensity focused ultrasound therapy in local site.
Study NCT04819516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab plus regorafenib
Study NCT05235893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Reflexology was applied to soles of the babies in the second study group during 5-7 minutes, three minutes before the painful procedure was started by a physiotherapist, certificated in reflexology.
Study NCT05235893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose %24
Description: The newborns who were given one ml of a single-use 24% concentration of sucrose solution in the form of ready to use preparations
Study NCT05235893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kangaroo care
Description: The newborns who were placed on the mother's lap for 3-5 minutes before the painful intervention and kangaroo care was applied
Study NCT05235893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Newborns who were exposed to the recorded Deep Sleep track from Bedtime Mozart: Classical Lullabies for Babies music
Study NCT02128373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Health care provided by physician, physician's nurse, and social worker
Study NCT02128373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Health care provided by physician, physician's nurse, and social worker
Study NCT02128373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer-assisted intervention
Description: Caregiver will virtually attend visit using the CLOSER intervention
Study NCT02128373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distress Thermometer
Description: Average score of a one item scale (range 0-10) where higher scores indicate more distress
Study NCT02128373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distress Thermometer
Description: Average score of a one item scale (range 0-10) where higher scores indicate more distress
Study NCT02128373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Profile of Mood States (POMS-B)
Description: average score of five items scored 0-4 which describe how someone is feeling. Higher scores indicate increased discomfort
Study NCT02128373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Profile of Mood States (POMS-B)
Description: average score of five items scored 0-4 which describe how someone is feeling. Higher scores indicate increased discomfort
Study NCT02128373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life: Functional Assessment in Cancer Therapy - (FACT)
Description: Average score of FACT which quantitatively assesses brain cancer patient's physiological functional and quality of life. FACT questions are scored 0-4 with higher numbers indicating more functionality
Study NCT02128373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life: Functional Assessment in Cancer Therapy - (FACT)
Description: Average score of FACT which quantitatively assesses brain cancer patient's physiological functional and quality of life. FACT questions are scored 0-4 with higher numbers indicating more functionality
Study NCT02128373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tension-Anxiety Subscale
Description: six item scale which asks to qualitatively describe which areas in you life are causing stress
Study NCT02128373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tension-Anxiety Subscale
Description: six item scale which asks to qualitatively describe which areas in you life are causing stress
Study NCT04219124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMP oral tablet
Description: Dapagliflozin 10 MG
Study NCT04219124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Matching placebo tablets
Study NCT01631149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surgical block (rocuronium; atracurium/mivacurium)
Description: The surgical block will be varied by either induction of a deep block (via rocuronium infusion) or a moderate/normal block (using atracurium/mivacurium infusion)
Study NCT01631149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surgical block (rocuronium; atracurium/mivacurium)
Description: A surgical block will be induced by infusion of either rocuronium (deep block) or atracurium/mivacurium (normal/moderate block)
Study NCT04027725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neurofeedback experiment will consist of 20 sessions of neurofeedback training, twice or three times a week during seven weeks. Each session will last for 40 minutes. The experimental group will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-trianing (T1) and 1 month follow-up (T2). Electroencephalography will be recorded by a technician in EEG for each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T1 and T2.
Study NCT01587846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of L.reuteri in children with abdominal pain
Description: Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
Study NCT01587846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of placebo in children with abdominal pain
Description: Group of around 75 children which will receive placebo for 3 months. The placebo consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
Study NCT01587846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of L.reuteri in children with constipation
Description: Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
Study NCT01587846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of placebo in children with constipation
Description: Group of around 75 children which will receive placebo plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The placebo study product consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
Study NCT01545037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®
Description: Each capsule contains 50 billion cfu live of Lactobacillus acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2® bacterias. The randomized subjects will consume 2 capsules per day at breakfast.
Study NCT01545037 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria.
Study NCT00818961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Description: 750 mg/m2 infused over 1 hour once daily on days -5, -4 and -3. Cyclophosphamide will be started approximately 4 hours after the start of Fludarabine
Study NCT00818961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fludarabine phosphate
Description: For patients with CLL, NHL \& HD: 30 mg/m2 infused over 30 minutes once daily on days -5, -4 and -3 For patients with AML, CML, MDS, MPS and ALL: 40 mg/m2 infused over 30 minutes once daily on days -6, -5, -4 and -3.
Study NCT00818961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: methotrexate
Description: 5 mg/m2 administered on days +1, +3 and +6
Study NCT00818961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tacrolimus
Description: 0.03mg/kg/day infused over 24 hours starting on day -1 and switched to oral (twice daily divided dose) on day 14 or when able to tolerate PO
Study NCT00818961 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: allogeneic bone marrow transplantation
Description: Recipients will receive an allogeneic transplant on day 0 after receiving high-dose chemotherapy. This trial uses matched unrelated donor stem cells.
Study NCT04373538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trans-C for sleep and circadian function + Memory Support
Description: The Memory Support Intervention will be delivered interwoven with Trans-C. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
Study NCT00683826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Leucine 8gr
Description: Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.
Study NCT00683826 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liquid meal
Description: Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.
Study NCT00683826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid meal
Description: Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.
Study NCT00683826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Leucine 4g
Description: Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.
Study NCT01423630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics and fruit fibre
Description: probiotics and fruit fibre
Study NCT03583255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT03583255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete resistance training and moderate intensity walking
Study NCT03583255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Complete resistance training and moderate intensity walking
Study NCT03583255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT00717860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin acetate
Description: Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
Study NCT00717860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Micafungin sodium
Description: Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
Study NCT00886444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferucarbotran (Resovist)
Description: single time intravenous bolus injection of a contrast agent
Study NCT00427921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 160 mg loading dose, 80 mg at week 2, 40 mg every other week
Study NCT02315404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAP
Description: CAP fitted to the end of the endoscope
Study NCT02315404 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CAP
Description: CAP fitted to the end of the endoscope
Study NCT01250574 — intervention group
Intervention type: OTHER
Intervention: CD64 and Procalcitonin
Description: Blood tests taken before and regularly after surgery or other treatment.
Study NCT02252393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo RARC with IUD
Study NCT02252393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo RARC with EUD
Study NCT02252393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intraoperative complication management/prevention
Description: Undergo RARC with IUD
Study NCT04536272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.
Study NCT04536272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH
Description: Administration of LMWH guided by weight and renal function during ECLS.
Study NCT04332042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib 10mg twice a day will be administered within 24h from hospital admission for 14 days
Study NCT01814592 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally partial thickness flap plus connective tissue
Description: The design of the flap will be performed according to the technique described by de Sanctis and Zucchelli 2007.
Study NCT01814592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronally mucosal thickness flap
Description: The design of the flap will be performed according to the technique described by Greenwell H, Vance G, Munninger B and Johnston H.
Study NCT01936025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Study NCT01936025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Study NCT01936025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study NCT01936025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04696666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSTYLAN (Sodium Hyaluronate 80mg/50ml)
Description: The bladder instillation with INSTYLAN is a treatment involving a sterile solution of Sodium Hyaluronate (80mg/50ml) inserted into the bladder through a catheter and released after a short period of time.
Study NCT04609033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: instillation of local anaesthetic in the abdominal cavity at the end of the procedure
Study NCT04609033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: instillation of local anaesthetic in the abdominal cavity at the end of the procedure
Study NCT04609033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine + morphine
Description: instillation of local anaesthetic + morphine sulfate in the abdominal cavity at the end of the procedure
Study NCT04609033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine + morphine + ketamine
Description: instillation of local anaesthetic + morphine sulfate + ketamine in the abdominal cavity at the end of the procedure
Study NCT02096523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection for platelet protein samples
Study NCT02306759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.3mg/kg in 50ml normal saline, administered over 15 minutes
Study NCT02306759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 50ml, administered over 15 minutes
Study NCT03661411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 100mg qd
Study NCT03661411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75mg
Description: 75mg（after first dose of 300mg）qd
Study NCT03661411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Iv at 0.9 milligrams per kilogram (mg/kg)
Study NCT02329054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Group A1: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group A2: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group C: daily dosages will be adapted to their body weight.
Study NCT02495025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based developmental screening and care coordination
Study NCT03505112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Description: The patients in GDT group will receive intravenous crystalloid fluid or vasopressor or inotropic agent according to the goal-directed therapy protocol utilizing FloTrac / EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA).~After induction of anesthesia, the baseline stroke volume index (SVI) is measured and then 200-250 ml of crystalloid is administered over 5-10 minutes. If SVI increase by ≥10%, 200-250 ml of crystalloid is given repeatedly until the increase in SVI \<10%. If SVI does not increase by ≥10% and there is no decrease in mean arterial pressure (MAP), revaluate SVI every 10 minutes. Despite an increase in SVI of \<10% after fluid challenge, if a decrease in MAP is accompanied by cardiac index (CI) ≤ 2.5 L/min/m2, dobutamine is administered by continuous infusion. If there is a decrease in MAP but no decrease in CI, start low dose norepinephrine continuous infusion.
Study NCT00336674 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal insulin
Description: 440IU Insulin
Study NCT00336674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo insulin carrier solution containing benzalkonium chloride and glycerol